Humacyte

Humacyte Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of Humacyte (HUMA) as of Nov 21, 2026 is 175.25. In the previous year, Cash Conversion Cycle (CCC) was -227.93 — a change of -176.89% (higher).

Cash Conversion Cycle

175.25

YoY

-176.89%

Last updated:

Cash Conversion Cycle (CCC) of Humacyte is 2025 175.25 . Cash Conversion Cycle (CCC) of Humacyte was 2024 -227.93 . It decreases by -176.89% higher compared to the previous year.

The Humacyte Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2019
19.60 USD
Jan 1, 2020
9.13 USD
Jan 1, 2021
45.34 USD
Jan 1, 2022
-71.89 USD
Jan 1, 2023
-30.95 USD
Jan 1, 2024
-227.93 USD
Jan 1, 2025
175.25 USD
The Humacyte Cash Conversion Cycle history
YEARCash Conversion CycleYoY
175.25-176.89%
-227.93+636.58%
-30.95-56.96%
-71.89-258.57%
45.34+396.49%
9.13-53.41%
19.60—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Humacyte Stock analysis

What does Humacyte do? Humacyte, Inc. develops and manufactures off-the-shelf, universally implantable bioengineered human tissues and advanced tissue constructs. The company focuses on human acellular vessels (HAVs) targeting vascular repair, reconstruction, and replacement markets, including vascular trauma, AV access for hemodialysis, peripheral arterial disease, and coronary artery bypass grafting. HAVs are also being developed for pediatric heart surgery and cellular therapies like pancreatic islet cell transplantation for Type 1 diabetes. The company's technology platform uses primary human aortic vascular cells to mimic human physiology. Humacyte's products are sold to healthcare providers and medical institutions for surgical procedures requiring tissue replacement. The vascular repair and hemodialysis markets represent key segments where HAVs address unmet clinical needs. Pediatric heart surgery applications target specialized medical centers, while cellular therapy delivery focuses on diabetes treatment centers. The company's novel manufacturing paradigm enables universal implantability without immune rejection. The firm's revenue streams derive from the sale of HAVs for vascular procedures and their expansion into pediatric and cellular therapy applications. Market segments include vascular surgery, nephrology for hemodialysis access, and endocrinology for diabetes treatment. HAVs are positioned as a solution for patients requiring tissue grafts with reduced risk of rejection compared to traditional methods. Humacyte is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Humacyte stock

Cash Conversion Cycle (CCC) of Humacyte is 175.25 in 2025.

Cash Conversion Cycle (CCC) of Humacyte changed from -227.93 to 175.25, representing a -176.89% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) Humacyte since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s Humacyte with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Humacyte

All Key Metrics — Humacyte